| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $1.9M | 0.00% | 11.63M | +855% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GOSS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 1, 2026 | Hasnain FaheemChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 280K | — |
| Jan 1, 2026 | Giraudo Bryan M.Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 115.8K | — |
| Jan 1, 2026 | Peterson CarynOfficer | Stock Award(Grant) at price 0.00 per share. | 84.5K | — |
| Jan 1, 2026 | Aranda RichardOfficer | Stock Award(Grant) at price 0.00 per share. | 93.8K | — |
| Jan 1, 2026 | Christian WaageOfficer | Stock Award(Grant) at price 0.00 per share. | 84.5K | — |
| Jan 1, 2026 | Smith Robert Paul JrOfficer | Stock Award(Grant) at price 0.00 per share. | 93.8K | — |
| Sep 30, 2025 | Hasnain FaheemChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 437.5K | — |
| Sep 30, 2025 | Giraudo Bryan M.Chief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 181.3K | — |
| Sep 30, 2025 | Peterson CarynOfficer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Sep 30, 2025 | Aranda RichardOfficer | Stock Award(Grant) at price 0.00 per share. | 162.5K | — |
| Sep 30, 2025 | Christian WaageOfficer | Stock Award(Grant) at price 0.00 per share. | 125K | — |
| Sep 30, 2025 | Smith Robert Paul JrOfficer | Stock Award(Grant) at price 0.00 per share. | 162.5K | — |
| Aug 18, 2025 | Milligan SandraDirector | Purchase at price 1.92 per share. | 26.1K | $50.02K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.5 | -81.4 | -22.6 | 11.9 | -37.2 | -28.6 | 3.0 | 0.0 | -12.9 | -17.3 | −96.0% | ||
| 2025 | 9.8 | 23.7 | -10.6 | -7.3 | 8.8 | 10.8 | 65.9 | 21.1 | 6.5 | -6.8 | 36.3 | -7.2 | +242.5% |
| 2024 | -8.0 | 67.9 | -16.3 | -39.8 | -16.9 | 52.7 | 0.2 | -2.8 | 12.3 | -11.0 | -20.5 | 29.7 | −0.9% |
| 2023 | 21.7 | -34.5 | -27.2 | 2.4 | 3.9 | -10.4 | 12.5 | -23.0 | -19.9 | -40.0 | 56.4 | 16.8 | −57.9% |
| 2022 | -15.2 | -5.8 | -3.9 | -20.4 | 2.0 | 18.7 | 34.2 | 24.2 | -14.1 | -7.3 | -22.9 | -74.6 | −80.8% |
| 2021 | 4.4 | -6.9 | -1.6 | -6.6 | -2.0 | -4.1 | -3.2 | 26.5 | 26.5 | -1.2 | -12.7 | 4.3 | +17.0% |
| 2020 | -15.0 | -1.1 | -22.7 | 28.3 | -6.7 | 7.0 | -8.3 | 16.6 | -10.7 | -33.1 | 6.5 | 9.4 | −38.1% |
| 2019 | -0.7 | -21.7 | 8.0 | 21.1 | -10.5 | 5.6 | -19.9 | 22.5 | 23.9 | -38.7 | −28.4% |
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Buy / hold / sell counts